Developer docs
API playgroundTry for free, no card

Search company profiles

4baseCare

Full company profile

uuid000219k

Namestring
4baseCare
Legal namestring
4baseCare Precision Health Private Limited
Websiteurl
4basecare.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

4baseCare Precision Health Private Limited is a Bengaluru-headquartered precision oncology company founded in 2019 by Hitesh Goswami (CEO) and Kshitij Rishi (COO). The company delivers AI-powered genomics solutions for cancer diagnosis, treatment selection, and clinical trial optimization, operating hospital-linked genomics laboratories across India, Dubai, Nepal, and the Philippines. Its core technology stack combines next-generation sequencing (NGS) with the proprietary OncoTwin AI platform, which creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data to support clinical decision-making, molecular tumor boards, and biomarker discovery.

The product portfolio spans five genomic test modalities (tissue profiling, liquid biopsy/ctDNA, SoLiQ dual-source, HRD/PARPredict, and germline testing), the Global Cancer Diversity Atlas (30,000+ genomic profiles from 15+ countries covering 70+ cancer types, with a stated focus on underrepresented Asian, Middle Eastern, and Southeast Asian populations), the OncoBuddy patient community platform, and patient access initiatives including the LuNGS Alliance (free NGS testing for lung cancer patients, covering 6,600+ patients across 700 cities) and the Hope Initiative with AIIMS Jammu. The company is an Illumina Accelerator portfolio company and was selected for the Memorial Sloan Kettering iHub Challenge 2025 Cohort.

4baseCare's revenue model combines fee-for-service genomic testing sold to hospitals and oncologists with platform licensing for OncoTwin to pharma companies and research institutions. GTM is enterprise field sales through hospital partnerships and lab collaborations, with a stated target of establishing 25 new lab collaborations and entering 8-10 additional countries within 12-18 months. Customer base includes hospital partners (Max Healthcare, AIIMS Jammu, Shankara Hospital, Caritas Hospitals), global pharma (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche via LuNGS Alliance), and emerging Tier-2/Tier-3 city hospitals. The company has been revenue-positive for five years with approximately ₹40 Cr in disclosed annual revenue, a ₹100 Cr revenue target for the next 12-18 months, and ₹130 Cr in Series B funding closed in 2026 at a ₹130 Cr post-money valuation.

Short descriptiontext

4baseCare is a precision oncology company that combines NGS-based genomic testing with the OncoTwin AI platform and a Global Cancer Diversity Atlas to deliver AI-powered cancer treatment decision support, serving hospitals, oncologists, and pharma companies across India, the Middle East, Southeast Asia, and emerging markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBengaluru, India
HQ citystring
Bengaluru
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology solutions, genomic profiling services, cancer diagnostics platform, AI clinical decision support, liquid biopsy testing
Industry5 codes
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cancer Genomics Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Genomic Testing Services
TypeOne Time License
Description

Revenue generated from comprehensive genomic profiling tests including tissue profiling, liquid biopsy, SoLiQ dual-source testing, HRD testing, and germline cancer risk testing. Sold directly to hospitals and healthcare providers through partnerships.

businessreviewlive.com
2AI Platform Services
TypeSubscription Recurring
Description

OncoTwin AI platform licensing for clinical decision support, molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharma companies.

economictimes.indiatimes.com
3Laboratory Services
TypeOne Time License
Description

Hospital-linked genomics laboratory services through partnerships. Labs established in India, Dubai, Nepal, and Philippines provide diagnostic services.

4basecare.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1B2B enterprise pricing through hospital partnerships
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing through hospital partnerships and direct B2B enterprise sales. Free NGS testing available through LuNGS Alliance for eligible lung cancer patients.

4basecare.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1OncoTwin
Description

AI-powered precision oncology platform that creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data

4basecare.com
+4 more records
Core offering1 text field

4baseCare delivers precision oncology through two integrated lines: (1) comprehensive genomic profiling tests (tissue, liquid biopsy/ctDNA, SoLiQ dual-source, HRD/PARPredict, and germline testing) performed in its hospital-linked genomics laboratories across India, UAE, Nepal, and the Philippines, and (2) the OncoTwin AI platform that creates digital twins of cancer patients by integrating multi-modal data to support clinical decision-making, molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 58% of 6,600+ lung cancer patients showed actionable mutations through LuNGS Alliance free testing
+2 more records
Product overview1 text field

4baseCare is a precision oncology company offering an integrated platform of genomics-based cancer diagnostics and AI-powered solutions. The portfolio centers on OncoTwin (AI-powered digital twin platform for treatment decisions), comprehensive Genomic Tests (tissue, liquid, SoLiQ, HRD, and germline testing), the Global Cancer Diversity Atlas (population-scale genomic data repository), and OncoBuddy (patient support app). The company operates hospital-linked genomics laboratories across India, Dubai, Nepal, and Philippines, supported by patient initiatives like LuNGS Alliance and Hope Initiative. This platform-plus-services architecture enables clinicians to access both AI-driven insights and direct diagnostic testing capabilities.

Product and service8 records
1OncoTwin AI Platform
CategoryAI Precision Oncology Software
Description

AI-powered precision oncology platform that creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data. Delivers clinical decision support with patient twin matching, AI-enhanced molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharmaceutical companies.

2Tissue Profiling (Solid Tumor Genomics)
CategoryGenomic Profiling Tests
Description

Comprehensive tumor DNA and RNA profiling from FFPE blocks that identifies actionable mutations, fusions, signatures, and resistance mechanisms to guide targeted, immunotherapy, and precision treatment decisions.

3Liquid Profiling (ctDNA Analysis)
CategoryGenomic Profiling Tests
Description

High-sensitivity circulating tumor DNA testing that detects actionable mutations, tracks treatment response, and overcomes tissue limitations through real-time, non-invasive genomic assessment for monitoring and treatment decisions.

4SoLiQ Dual-Source Genomics
CategoryGenomic Profiling Tests
Description

Combined tissue-liquid-germline approach that overcomes tumor heterogeneity, confirms true somatic variants, and delivers the most complete and clinically confident genomic picture for each patient.

5HRD Testing (PARPredict)
CategoryGenomic Profiling Tests
Description

Scar-based homologous recombination deficiency assay that measures genomic instability to identify HRD-positive tumors more accurately than BRCA-only testing, enabling confident PARP inhibitor therapy selection.

6Germline Cancer Risk & Treatment Insights
CategoryGenomic Profiling Tests
Description

Accurate hereditary cancer testing that identifies inherited risk variants, informs treatment sensitivity such as PARP inhibitor eligibility, and supports family counseling and preventive care.

7Global Cancer Diversity Atlas (GCDA)
CategoryGenomic Data Platform
Description

Population-scale genomic data repository with 30,000+ genomic profiles from 15+ underrepresented populations, covering 30+ rare and under-studied cancers and 70+ cancer types with integrated tumor, germline, liquid biopsy, clinical, and outcomes datasets.

8OncoBuddy Patient App
CategoryPatient Support Platform
Description

Patient support platform and mobile app (available on Google Play and Apple App Store) that enables cancer patients and caregivers to share their cancer journey with other survivors, access community support, and receive affordable genetic testing assistance.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Bio Valley and Define Bio (P) Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

MoU to establish BioSphere Center of Excellence for Genomics and Next-Generation Sequencing at Andhra Pradesh MedTech Zone in Visakhapatnam. Initiative to strengthen India's genomic infrastructure and generate datasets reflecting India's genetic diversity.

indianweb2.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Collaboration to advance inclusive precision oncology research. Partnership aims to utilize diverse, large-scale datasets to enhance therapeutic research and address underrepresentation of Asian and Middle Eastern populations in pharmaceutical research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Partnership with Caritas Hospitals to bring personalised cancer care to patients in Kerala, India. Aims to advance inclusive AI-driven cancer research using genomic solutions.

4AIIMS Jammu
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-22
Description

MoU to launch Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu. Hope Initiative makes advanced genomic testing affordable and accessible for cancer patients.

businessreviewlive.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-25
Description

Partnership at Dubai Science Park to unlock genomics research for precision oncology in the Middle East region.

6Francis deSouza
Strategic tierMinorTypeOthersAnnounced on2024-08-27
Description

Former CEO of Illumina, a Silicon Valley tech veteran, joined 4baseCare's Advisory Board.

4basecare.com
Strategic tierCoreTypeTechnology or Integration
Description

Illumina Accelerator Company - 4baseCare is backed by Illumina and operates as part of their accelerator program. Illumina provides sequencing technology and partnership for technology development.

8LuNGS Alliance (CRSF & 4baseCare)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration between oncologists, government hospitals, pharma companies (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche), Tata Capital, and 4baseCare providing free NGS tests to lung cancer patients. Provided 6,600+ tests across 700 cities.

straitsresearch.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hospital partnership for decentralized genomic testing infrastructure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hospital partnership for genomic testing services.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

OncoTwin platform selected for testing on MSK datasets through MSK iHub programme. Provides international validation for the AI platform.

12Lip-Bu Tan
Strategic tierMinorTypeOthers
Description

Tech visionary and venture capitalist joined 4baseCare's advisory board.

whalesbook.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India- and US-based genomics company offering NGS-based diagnostics and research services across oncology, reproductive health, and rare diseases. Most direct competitor to 4baseCare in Indian precision oncology.

TypeDirect peer
Description

India-based genomics and bioinformatics company providing NGS diagnostics and clinical interpretation services. Directly comparable on genomic testing plus clinical decision support, with similar hospital-linked distribution model.

TypeDirect peer
Description

India- and UK-based precision oncology company offering circulating tumor cell and cell-free DNA-based tests for cancer detection, treatment selection, and monitoring. Comparable oncology liquid biopsy and treatment-guidance offering.

TypeDirect peer
Description

US-based precision oncology company offering comprehensive molecular profiling (tissue and liquid) plus an AI-driven clinical decision support platform (MI Profile). Closest global analogue to 4baseCare's combined testing + AI platform model.

5Tempus AI
TypeDirect peer
Description

US-based AI-powered precision medicine company combining large-scale genomic and clinical data with AI for oncology decision support. Comparable in combining NGS testing with AI platform and pharma R&D services.

TypeBroad incumbent
Description

US-based NGS oncology profiling leader owned by Roche. Operates at significantly larger scale and provides similar comprehensive genomic profiling services, making it the dominant global incumbent against which 4baseCare competes for international pharma partnerships.

TypeDirect peer
Description

US-based precision oncology company specializing in liquid biopsy (ctDNA) for therapy selection and monitoring. Direct overlap on liquid profiling tests (a core 4baseCare product) and broader oncology diagnostics.

TypeDirect peer
Description

US-based genomics company offering tumor profiling and immuno-oncology biomarker tests, with pharma services including clinical trial patient enrollment support. Comparable on NGS oncology + pharma R&D services model.

TypeDirect peer
Description

US-based cell-free DNA testing company with growing oncology business (Signatera MRD test). Comparable on tumor-informed liquid biopsy and pharma services, though more oncology-adjacent than pure-play.

10MGI Tech
TypeOthers
Description

China-based sequencing technology provider (part of BGI Group) and one of the underlying platforms 4baseCare uses alongside Illumina. Relevant as both an enabler and a potential competitor for low-cost NGS oncology in emerging markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

4baseCare

Cancer Genomics Diagnostics4basecare.com

4baseCare is a precision oncology company that combines NGS-based genomic testing with the OncoTwin AI platform and a Global Cancer Diversity Atlas to deliver AI-powered cancer treatment decision support, serving hospitals, oncologists, and pharma companies across India, the Middle East, Southeast Asia, and emerging markets.

What 4baseCare does

4baseCare Precision Health Private Limited is a Bengaluru-headquartered precision oncology company founded in 2019 by Hitesh Goswami (CEO) and Kshitij Rishi (COO). The company delivers AI-powered genomics solutions for cancer diagnosis, treatment selection, and clinical trial optimization, operating hospital-linked genomics laboratories across India, Dubai, Nepal, and the Philippines. Its core technology stack combines next-generation sequencing (NGS) with the proprietary OncoTwin AI platform, which creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data to support clinical decision-making, molecular tumor boards, and biomarker discovery.

The product portfolio spans five genomic test modalities (tissue profiling, liquid biopsy/ctDNA, SoLiQ dual-source, HRD/PARPredict, and germline testing), the Global Cancer Diversity Atlas (30,000+ genomic profiles from 15+ countries covering 70+ cancer types, with a stated focus on underrepresented Asian, Middle Eastern, and Southeast Asian populations), the OncoBuddy patient community platform, and patient access initiatives including the LuNGS Alliance (free NGS testing for lung cancer patients, covering 6,600+ patients across 700 cities) and the Hope Initiative with AIIMS Jammu. The company is an Illumina Accelerator portfolio company and was selected for the Memorial Sloan Kettering iHub Challenge 2025 Cohort.

4baseCare's revenue model combines fee-for-service genomic testing sold to hospitals and oncologists with platform licensing for OncoTwin to pharma companies and research institutions. GTM is enterprise field sales through hospital partnerships and lab collaborations, with a stated target of establishing 25 new lab collaborations and entering 8-10 additional countries within 12-18 months. Customer base includes hospital partners (Max Healthcare, AIIMS Jammu, Shankara Hospital, Caritas Hospitals), global pharma (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche via LuNGS Alliance), and emerging Tier-2/Tier-3 city hospitals. The company has been revenue-positive for five years with approximately ₹40 Cr in disclosed annual revenue, a ₹100 Cr revenue target for the next 12-18 months, and ₹130 Cr in Series B funding closed in 2026 at a ₹130 Cr post-money valuation.

4baseCare firmographics

Firmographics
Name
4baseCare
Legal name
4baseCare Precision Health Private Limited
Website
https://4basecare.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
251–500 employees
Short description
4baseCare is a precision oncology company that combines NGS-based genomic testing with the OncoTwin AI platform and a Global Cancer Diversity Atlas to deliver AI-powered cancer treatment decision support, serving hospitals, oncologists, and pharma companies across India, the Middle East, Southeast Asia, and emerging markets.
Ownership category
akta.pro rank

4baseCare industry classification

Industry
Product category
Cancer Genomics Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Precision oncology solutions
  • Genomic profiling services
  • Cancer diagnostics platform
  • AI clinical decision support
  • Liquid biopsy testing

Where 4baseCare is headquartered

Location

Headquarters

HQ city
Bengaluru
HQ country
India
HQ region
Asia

Offices7 records

Markets served

4baseCare business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Genomic Testing Services: Revenue generated from comprehensive genomic profiling tests including tissue profiling, liquid biopsy, SoLiQ dual-source testing, HRD testing, and germline cancer risk testing. Sold directly to hospitals and healthcare providers through partnerships.
  2. AI Platform Services: OncoTwin AI platform licensing for clinical decision support, molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharma companies.
  3. Laboratory Services: Hospital-linked genomics laboratory services through partnerships. Labs established in India, Dubai, Nepal, and Philippines provide diagnostic services.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goB2B enterprise pricing through hospital partnerships

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

4baseCare product offering

Product offering

Core offering

4baseCare delivers precision oncology through two integrated lines: (1) comprehensive genomic profiling tests (tissue, liquid biopsy/ctDNA, SoLiQ dual-source, HRD/PARPredict, and germline testing) performed in its hospital-linked genomics laboratories across India, UAE, Nepal, and the Philippines, and (2) the OncoTwin AI platform that creates digital twins of cancer patients by integrating multi-modal data to support clinical decision-making, molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharmaceutical companies.

Product overview

4baseCare is a precision oncology company offering an integrated platform of genomics-based cancer diagnostics and AI-powered solutions. The portfolio centers on OncoTwin (AI-powered digital twin platform for treatment decisions), comprehensive Genomic Tests (tissue, liquid, SoLiQ, HRD, and germline testing), the Global Cancer Diversity Atlas (population-scale genomic data repository), and OncoBuddy (patient support app). The company operates hospital-linked genomics laboratories across India, Dubai, Nepal, and Philippines, supported by patient initiatives like LuNGS Alliance and Hope Initiative. This platform-plus-services architecture enables clinicians to access both AI-driven insights and direct diagnostic testing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • OncoTwin: AI-powered precision oncology platform that creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data
  • OncoBuddy
  • Global Cancer Diversity Atlas (GCDA)
  • LuNGS Alliance
  • Hope Initiative

Products and services

  • OncoTwin AI Platform AI-powered precision oncology platform that creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data. Delivers clinical decision support with patient twin matching, AI-enhanced molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharmaceutical companies.
  • Tissue Profiling (Solid Tumor Genomics) Comprehensive tumor DNA and RNA profiling from FFPE blocks that identifies actionable mutations, fusions, signatures, and resistance mechanisms to guide targeted, immunotherapy, and precision treatment decisions.
  • Liquid Profiling (ctDNA Analysis) High-sensitivity circulating tumor DNA testing that detects actionable mutations, tracks treatment response, and overcomes tissue limitations through real-time, non-invasive genomic assessment for monitoring and treatment decisions.
  • SoLiQ Dual-Source Genomics Combined tissue-liquid-germline approach that overcomes tumor heterogeneity, confirms true somatic variants, and delivers the most complete and clinically confident genomic picture for each patient.
  • HRD Testing (PARPredict) Scar-based homologous recombination deficiency assay that measures genomic instability to identify HRD-positive tumors more accurately than BRCA-only testing, enabling confident PARP inhibitor therapy selection.
  • Germline Cancer Risk & Treatment Insights Accurate hereditary cancer testing that identifies inherited risk variants, informs treatment sensitivity such as PARP inhibitor eligibility, and supports family counseling and preventive care.
  • Global Cancer Diversity Atlas (GCDA) Population-scale genomic data repository with 30,000+ genomic profiles from 15+ underrepresented populations, covering 30+ rare and under-studied cancers and 70+ cancer types with integrated tumor, germline, liquid biopsy, clinical, and outcomes datasets.
  • OncoBuddy Patient App Patient support platform and mobile app (available on Google Play and Apple App Store) that enables cancer patients and caregivers to share their cancer journey with other survivors, access community support, and receive affordable genetic testing assistance.

Quantifiable outcome

  • 58% of 6,600+ lung cancer patients showed actionable mutations through LuNGS Alliance free testing
  • +2 more outcomes

Companies that use 4baseCare

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

4baseCare technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

4baseCare partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, minor and major.

  • Bio Valley and Define Bio (P) Ltd.coreStrategic or Co-development Partner · 3 March 2026MoU to establish BioSphere Center of Excellence for Genomics and Next-Generation Sequencing at Andhra Pradesh MedTech Zone in Visakhapatnam. Initiative to strengthen India's genomic infrastructure and generate datasets reflecting India's genetic diversity.
  • OwkincoreStrategic or Co-development Partner · 18 February 2026Collaboration to advance inclusive precision oncology research. Partnership aims to utilize diverse, large-scale datasets to enhance therapeutic research and address underrepresentation of Asian and Middle Eastern populations in pharmaceutical research.
  • Caritas HospitalscoreStrategic or Co-development Partner · 1 June 2025Partnership with Caritas Hospitals to bring personalised cancer care to patients in Kerala, India. Aims to advance inclusive AI-driven cancer research using genomic solutions.
  • AIIMS JammucoreStrategic or Co-development Partner · 22 January 2025MoU to launch Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu. Hope Initiative makes advanced genomic testing affordable and accessible for cancer patients.
  • Innovate Life SciencescoreStrategic or Co-development Partner · 25 October 2024Partnership at Dubai Science Park to unlock genomics research for precision oncology in the Middle East region.
  • Francis deSouzaminorOthers · 27 August 2024Former CEO of Illumina, a Silicon Valley tech veteran, joined 4baseCare's Advisory Board.
  • IlluminacoreTechnology or IntegrationIllumina Accelerator Company - 4baseCare is backed by Illumina and operates as part of their accelerator program. Illumina provides sequencing technology and partnership for technology development.
  • LuNGS Alliance (CRSF & 4baseCare)coreStrategic or Co-development PartnerCollaboration between oncologists, government hospitals, pharma companies (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche), Tata Capital, and 4baseCare providing free NGS tests to lung cancer patients. Provided 6,600+ tests across 700 cities.
  • Max HealthcarecoreStrategic or Co-development PartnerHospital partnership for decentralized genomic testing infrastructure.
  • Shankara HospitalcoreStrategic or Co-development PartnerHospital partnership for genomic testing services.
  • Memorial Sloan Kettering Cancer Center (MSK)majorStrategic or Co-development PartnerOncoTwin platform selected for testing on MSK datasets through MSK iHub programme. Provides international validation for the AI platform.
  • Lip-Bu TanminorOthersTech visionary and venture capitalist joined 4baseCare's advisory board.

Scale indicators15 records

Recent moves8 records

Expansion highlights5 records

4baseCare competitors and assessment

Company assessment

Direct peers

  • MedGenome: India- and US-based genomics company offering NGS-based diagnostics and research services across oncology, reproductive health, and rare diseases. Most direct competitor to 4baseCare in Indian precision oncology.
  • Strand Life Sciences: India-based genomics and bioinformatics company providing NGS diagnostics and clinical interpretation services. Directly comparable on genomic testing plus clinical decision support, with similar hospital-linked distribution model.
  • Datar Cancer Genetics: India- and UK-based precision oncology company offering circulating tumor cell and cell-free DNA-based tests for cancer detection, treatment selection, and monitoring. Comparable oncology liquid biopsy and treatment-guidance offering.
  • Caris Life Sciences: US-based precision oncology company offering comprehensive molecular profiling (tissue and liquid) plus an AI-driven clinical decision support platform (MI Profile). Closest global analogue to 4baseCare's combined testing + AI platform model.
  • Tempus AI: US-based AI-powered precision medicine company combining large-scale genomic and clinical data with AI for oncology decision support. Comparable in combining NGS testing with AI platform and pharma R&D services.
  • Guardant Health: US-based precision oncology company specializing in liquid biopsy (ctDNA) for therapy selection and monitoring. Direct overlap on liquid profiling tests (a core 4baseCare product) and broader oncology diagnostics.
  • Personalis: US-based genomics company offering tumor profiling and immuno-oncology biomarker tests, with pharma services including clinical trial patient enrollment support. Comparable on NGS oncology + pharma R&D services model.
  • Natera: US-based cell-free DNA testing company with growing oncology business (Signatera MRD test). Comparable on tumor-informed liquid biopsy and pharma services, though more oncology-adjacent than pure-play.

Broad incumbents

  • Foundation Medicine (Roche): US-based NGS oncology profiling leader owned by Roche. Operates at significantly larger scale and provides similar comprehensive genomic profiling services, making it the dominant global incumbent against which 4baseCare competes for international pharma partnerships.

Others

  • MGI Tech: China-based sequencing technology provider (part of BGI Group) and one of the underlying platforms 4baseCare uses alongside Illumina. Relevant as both an enabler and a potential competitor for low-cost NGS oncology in emerging markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

4baseCare social profiles

Digital presence

4baseCare compliance and trust

Trust signal

Compliance1 record

4baseCare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

4baseCare leadership team

Management profile

Number of profiles

Profiles5 records

4baseCare funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

4baseCare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4baseCare

What does 4baseCare do?

4baseCare delivers precision oncology through two integrated lines: (1) comprehensive genomic profiling tests (tissue, liquid biopsy/ctDNA, SoLiQ dual-source, HRD/PARPredict, and germline testing) performed in its hospital-linked genomics laboratories across India, UAE, Nepal, and the Philippines, and (2) the OncoTwin AI platform that creates digital twins of cancer patients by integrating multi-modal data to support clinical decision-making, molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharmaceutical companies.

Is 4baseCare a public or private company?

4baseCare is a private company. It is classified as venture growth investor backed and is currently operating.

When was 4baseCare founded?

4baseCare was founded in 2019. It employs 251 to 500 people.

Where is 4baseCare based?

4baseCare is headquartered in Bengaluru, India, in the Asia region.

How does 4baseCare make money?

Three revenue lines are on record. Genomic Testing Services are the primary driver. The others are AI Platform Services and laboratory Services.

Who are 4baseCare's main competitors?

Direct peers on record are MedGenome, Strand Life Sciences, Datar Cancer Genetics, Caris Life Sciences, Tempus AI, Guardant Health, Personalis and Natera. Foundation Medicine (Roche) is listed as a broad incumbent. MGI Tech is listed as an others.

Does 4baseCare have an API?

No public API is recorded for 4baseCare.

What industry is 4baseCare in?

4baseCare's product category is Cancer Genomics Diagnostics. Its primary akta.pro industry code is HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
exchange4mediaKanchan Saini joins 4baseCare as Head of Marketing - Exchange4mediaKanchan Saini joined 4baseCare as Head of Marketing, bringing healthcare marketing experience. She previously served as General Manager – Marketing, Specialized Business at LifeCell International from July 2025 to October 2026, and held earlier roles at Dr Lal PathLabs and MEDGENOME.Digital Health News4baseCare Partners With Cancer Institute to Expand Precision Oncology Access Across Chennai4baseCare, a Bengaluru precision oncology startup, partnered with Cancer Institute (WIA) in Chennai to expand access to genomic testing for cancer patients. The collaboration aims to bring molecular insights closer to point of care, and 4baseCare recently closed a Series B at INR 128 crore, including a INR 38 crore top-up.The Times of India4baseCare expands cancer profiling panel with 2,206-gene Indiegene V2 - The Economic TimesPrecision oncology startup 4baseCare has launched Indiegene V2, a comprehensive genomic profiling test that expands its panel to 2,206 genes to improve the detection of clinically relevant cancer biomarkers. This update follows the original 1,212-gene panel launched in August 2021, which was developed using genomic data from Indian patients to address gaps in Western-centric datasets.IndiaWeb24baseCare Launches Targt Indiegene® V2, Bringing A Biology-First Approach to Comprehensive Cancer Profiling4baseCare launched TARGT Indiegene V2, a next-generation comprehensive genomic profiling test covering 2,206 genes. The test adds Hallmarks of Cancer-led profiling, HRD scoring, 36 HRR genes, and 299 fusions, with an individualized Tumour Mutation Burden score. The company aims to make precision oncology accessible across diverse populations.ChemindigestFirst Batch of Biotech Startups Selected for Funding Under ₹1 Trillion R&D InitiativeIndia has selected the first batch of five biotechnology startups—Fermbox Bio, Sea6 Energy, Revelations Biotech, 4baseCare, and Telluris Biotech—for funding under its ₹1 trillion Research, Development and Innovation (RDI) initiative, with the Biotechnology Industry Research Assistance Council overseeing the selection. The first group of projects could receive approximately ₹450 crore in government support, structured as co-funding where participating companies must contribute the remaining project costs. The initiative aims to reduce India's dependence on imported biotech products, build domestic manufacturing capabilities, and accelerate commercialization of research in synthetic biology and biofuels as part of a broader national innovation strategy targeting sectors including AI, Robotics, Space Technology, Healthcare, and Energy Security.https://www.outlookbusiness.com/Who Made the Cut? Govt Selects First Biotech Startups for RDI Fund – Outlook BusinessBIRAC has selected seven to eight biotech startups for the first cohort of funding under the government's ₹1 trillion Research, Development and Innovation (RDI) Fund. The selected companies include Fermbox Bio, Revelations Biotech, Sea6 Energy, 4baseCare, and Telluris Biotech, each expected to receive around ₹25 crore on average. BIRAC received nearly 200 applications after inviting proposals in February, with an official announcement expected in the coming weeks.https://www.outlookbusiness.com/Who Made the Cut? Govt Selects First Biotech Startups for RDI Fund – Outlook BusinessBIRAC (Biotechnology Industry Research Assistance Council) has selected seven to eight biotechnology startups for the first funding round under the government's ₹1 trillion Research, Development and Innovation (RDI) Fund. The first cohort includes Fermbox Bio, Revelations Biotech, Sea6 Energy, 4baseCare, and Telluris Biotech, with each startup expected to receive around ₹25 crore on average. Agreements with Fermbox Bio, Revelations Biotech, and Sea6 Energy alone are collectively valued at approximately ₹450 crore, with an official announcement expected in the coming weeks.Business StandardFirst set of biotech startups picked for funding under ₹1 trillion R&D pushThe Biotechnology Industry Research Assistance Council (BIRAC) has selected seven to eight biotechnology startups as the first cohort to receive funding under the Indian government's ₹1 trillion Research, Development and Innovation (RDI) Fund. The selected startups include Fermbox Bio, Revelations Biotech, 4baseCare, Sea6 Energy and Telluris Biotech, with an expected average investment of about ₹25 crore per startup. BIRAC received nearly 200 applications after inviting proposals in February and has so far screened approximately 50 proposals.The Economic TimesInfosys-backed 4baseCare raises Rs 128 crore, plans to take its cancer testing platform globalBengaluru-based precision oncology startup 4baseCare has raised Rs 128 crore in a funding round led by growX Ventures with participation from Infosys and existing investors, including a Rs 38 crore top-up tranche. The capital will fund global expansion of its genomics laboratory network and scaling of its AI-led oncology platform OncoTwin, with plans to enter 8-10 additional countries over the next 12-18 months. The company, which currently operates labs in India, Dubai, Nepal, and the Philippines and generates around Rs 40 crore in annual revenues, aims to make precision oncology more inclusive for under-represented populations globally.The Times of IndiaScanning cancer, up close & personal: A revolution is underway in cancer diagnosis - The Economic TimesNext-generation sequencing (NGS), a gene-based diagnostic test, is transforming cancer diagnosis in India by identifying precise genetic mutations for targeted therapies. The LuNGS Alliance—a collaboration between oncologists, government hospitals, pharma companies (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche), Tata Capital, and startup 4baseCare—has provided free NGS tests to over 6,600 lung cancer patients across 700 cities since March 2025, with 58% showing actionable mutations. India's genome sequencing market is projected to reach $1.5 billion by 2030, though high drug costs remain a barrier to widespread adoption of precision medicine.